ROCKET PHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Stock Option Valuation
The weighted average assumptions that the Company used in a Black-Scholes pricing model to determine the fair value of stock options granted to employees, non-employees and directors were as follows:
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Risk-free interest rate | 4.19% | 4.85% |
| Expected term (in years) | 5.51 | 5.82 |
| Expected volatility | 75.33% | 73.70% |
| Expected dividend yield | 0.00% | 0.00% |
| Exercise price | $8.62 | $27.24 |
| Fair value of common stock | $8.62 | $27.24 |
The following table summarizes stock option activity for thenine months ended September 30, 2025:
| Weighted · Weighted | |||||
|---|---|---|---|---|---|
| Average · Average · Aggregate | |||||
| Number of · Exercise · Contractual · Intrinsic | |||||
| Shares · Price · Term (Years) · Value | |||||
| Outstanding as of December 31, 2024 | 16,044,686 | $16.19 | 4.67 | $63,295 | |
| Granted | 2,243,352 | 8.62 | 8.26 | ||
| Exercised | (952,313) | 0.00 | - | ||
| Cancelled or forfeited | (664,722) | 20.17 | |||
| Outstanding as of September 30, 2025 | 16,671,003 | $15.94 | 4.18 | $9,935 | |
| Options vested and exercisable as of September 30, 2025 | 13,776,919 | $16.51 | 3.25 | $9,823 | |
| Options unvested as of September 30, 2025 | 2,894,084 | $13.20 | 8.61 | $112 | |
The weighted average grant-date fair value per share of stock options granted during the nine months ended September 30, 2025, and 2024 was$5.15 and$18.34, respectively.
The total fair value of options vested during the nine months ended September 30, 2025, and 2024 was$24.0 million and$23.6 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.